Nuo Therapeutics, Inc.: capital expenditure payments
Capital expenditure payments for Nuo Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Nuo Therapeutics, Inc. financial histories
What this measure means
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
Exact concept: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2010-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 274,756 | USD | 2026-03-30 | 10-K · 0001437749-26-010360 |
| 2024-01-01 | 2024-12-31 | 154,962 | USD | 2026-03-30 | 10-K · 0001437749-26-010360 |
| 2023-01-01 | 2023-12-31 | 7,244 | USD | 2025-04-01 | 10-K · 0001437749-25-010379 |
| 2022-01-01 | 2022-12-31 | 59,992 | USD | 2024-04-19 | 10-K · 0001437749-24-012587 |
| 2021-01-01 | 2021-12-31 | 0 | USD | 2023-04-17 | 10-K · 0001437749-23-010351 |
| 2020-01-01 | 2020-12-31 | 0 | USD | 2022-04-15 | 10-K · 0001437749-22-009050 |
| 2019-01-01 | 2019-12-31 | 0 | USD | 2022-04-15 | 10-K · 0001437749-22-009050 |
| 2015-01-01 | 2015-12-31 | 698,172 | USD | 2016-10-24 | 10-K · 0001144204-16-129029 |
| 2014-01-01 | 2014-12-31 | 482,962 | USD | 2016-10-24 | 10-K · 0001144204-16-129029 |
| 2013-01-01 | 2013-12-31 | 750,697 | USD | 2015-03-31 | 10-K · 0001144204-15-020277 |
| 2011-01-01 | 2011-12-31 | 66,430 | USD | 2012-03-29 | 10-K · 0001144204-12-018103 |
| 2010-01-01 | 2010-12-31 | 774,625 | USD | 2012-03-29 | 10-K · 0001144204-12-018103 |
Related financial histories
- Nuo Therapeutics, Inc.: total assets
- Nuo Therapeutics, Inc.: total liabilities
- Nuo Therapeutics, Inc.: stockholders equity
- Nuo Therapeutics, Inc.: cash and cash equivalents
- Nuo Therapeutics, Inc.: net income or loss
- Nuo Therapeutics, Inc.: operating cash flow
- Nuo Therapeutics, Inc.: revenue
- Nuo Therapeutics, Inc.: financing cash flow
- Nuo Therapeutics, Inc.: investing cash flow
- Nuo Therapeutics, Inc.: retained earnings or deficit
- Nuo Therapeutics, Inc.: basic weighted-average shares
- Nuo Therapeutics, Inc.: diluted weighted-average shares
- Nuo Therapeutics, Inc.: basic earnings per share
- Nuo Therapeutics, Inc.: diluted earnings per share
- Nuo Therapeutics, Inc.: income tax expense or benefit
- Nuo Therapeutics, Inc.: net property, plant and equipment
- Nuo Therapeutics, Inc.: share-based compensation expense
- Nuo Therapeutics, Inc.: operating income or loss
- Nuo Therapeutics, Inc.: current assets
- Nuo Therapeutics, Inc.: current liabilities
- Nuo Therapeutics, Inc.: current accounts payable
- Nuo Therapeutics, Inc.: goodwill carrying amount
- Nuo Therapeutics, Inc.: net current accounts receivable
- Nuo Therapeutics, Inc.: operating expenses
- Nuo Therapeutics, Inc.: net inventory
- Nuo Therapeutics, Inc.: gross profit
- Nuo Therapeutics, Inc.: cost of revenue
- Nuo Therapeutics, Inc.: selling, general and administrative expense
- Nuo Therapeutics, Inc.: research and development expense
Inspect the source
- Entity
- Nuo Therapeutics, Inc. / CIK 0001091596
- Captured
- 2026-09-20T05:21:57.848Z
- SEC response SHA-256
f9d1094a0912aec87dd50c0e6f3c9b7f90d3de5f7435cbf00ae5d71aa22d4723
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001091596.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))